Different immunotherapies have achieved remarkable results in the treatment of a variety of cancers, but there are also limitations such as low response and acquired drug resistance that reduce the efficacy of cancer immunotherapy. However, conventional chemo/radiotherapy can change the state of tumor immune microenvironments in situ, thus enhancing immunotherapy’s efficacy. In consequence, the combination of immunotherapy may overcome these shortcomings. For example, radiotherapy can change the immune microenvironments of the tumor by modulating the immune response. Different low-dose fractionated radiotherapy can lead to immunogenic cell death in the immune microenvironments of tumor tissues and in situ vaccination of tumors, while immunotherapeutic drugs can enhance the remote effect of tumor radiotherapy, demonstrating the possibility of the synergistic effect of radiotherapy and immunotherapy in tumor treatment. In addition, some studies have demonstrated the immune principle and molecular basis of immunotherapy combined with chemotherapy in the treatment of advanced non-small cell lung cancer demonstrated that tumor cells escape from the attack of the immune system through a variety of mechanisms, and suggested that more and better chemo-immunotherapy combinations should be selected, and immunosuppressive agent combined with chemotherapy drugs is a promising method for cancer treatment. Moreover, new tumor biomarkers can be found to identify patients who respond to immunoradiotherapy and to explore some mechanisms to overcome drug resistance.
This research topic presents discoveries and new schemes of various combination immunotherapies for different cancers by analysis of tumor immune microenvironments and molecular mechanisms, including new immune checkpoints, mechanisms of regulation of different immune cells in the tumor immune microenvironments under various combination immunotherapies, discovery of new cancer biomarkers and mechanisms of overcoming tumor immune resistance, etc. To facilitate communication and mutual learning among researchers in this field, various types of papers are allowed to be submitted.
We welcome manuscripts from the following subtopics:
1. Cancer neoantigens as immunotherapy biomarkers
2. TCR/BCR as immunotherapy biomarkers
3. Therapeutic targeting of the cancer microenvironments
4. Chimeric antigen receptor (CAR) T-cell for cancer immunotherapy
5. Cancer stem cells for cellular immunotherapy
6. Macrophage-Based methods for cancer immunotherapy
7. Tumor-infiltrating lymphocytes for cancer immunotherapy
8. Cancer immune response and mechanisms of resistance to immunotherapy
9. Targeted metabolism in NSCLC immunotherapy
Please note: Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section.
Different immunotherapies have achieved remarkable results in the treatment of a variety of cancers, but there are also limitations such as low response and acquired drug resistance that reduce the efficacy of cancer immunotherapy. However, conventional chemo/radiotherapy can change the state of tumor immune microenvironments in situ, thus enhancing immunotherapy’s efficacy. In consequence, the combination of immunotherapy may overcome these shortcomings. For example, radiotherapy can change the immune microenvironments of the tumor by modulating the immune response. Different low-dose fractionated radiotherapy can lead to immunogenic cell death in the immune microenvironments of tumor tissues and in situ vaccination of tumors, while immunotherapeutic drugs can enhance the remote effect of tumor radiotherapy, demonstrating the possibility of the synergistic effect of radiotherapy and immunotherapy in tumor treatment. In addition, some studies have demonstrated the immune principle and molecular basis of immunotherapy combined with chemotherapy in the treatment of advanced non-small cell lung cancer demonstrated that tumor cells escape from the attack of the immune system through a variety of mechanisms, and suggested that more and better chemo-immunotherapy combinations should be selected, and immunosuppressive agent combined with chemotherapy drugs is a promising method for cancer treatment. Moreover, new tumor biomarkers can be found to identify patients who respond to immunoradiotherapy and to explore some mechanisms to overcome drug resistance.
This research topic presents discoveries and new schemes of various combination immunotherapies for different cancers by analysis of tumor immune microenvironments and molecular mechanisms, including new immune checkpoints, mechanisms of regulation of different immune cells in the tumor immune microenvironments under various combination immunotherapies, discovery of new cancer biomarkers and mechanisms of overcoming tumor immune resistance, etc. To facilitate communication and mutual learning among researchers in this field, various types of papers are allowed to be submitted.
We welcome manuscripts from the following subtopics:
1. Cancer neoantigens as immunotherapy biomarkers
2. TCR/BCR as immunotherapy biomarkers
3. Therapeutic targeting of the cancer microenvironments
4. Chimeric antigen receptor (CAR) T-cell for cancer immunotherapy
5. Cancer stem cells for cellular immunotherapy
6. Macrophage-Based methods for cancer immunotherapy
7. Tumor-infiltrating lymphocytes for cancer immunotherapy
8. Cancer immune response and mechanisms of resistance to immunotherapy
9. Targeted metabolism in NSCLC immunotherapy
Please note: Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section.
